Methods and compositions for disrupting biofilm utilizing chitosan-derivative compounds
Described herein are methods of disrupting (e.g., reducing the viscosity of, or dissolving) a preformed biofilm in a subject, the method comprising: administering to the subject an effective amount of a composition comprising a soluble chitosan or derivatized chitosan wherein the soluble chitosan or derivatized chitosan when administered contacts the preformed biofilm, thereby disrupting (e.g., reducing the viscosity of, or dissolving) the preformed biofilm.
1. A method of reducing the viscosity of viscous sputum in the respiratory system of a human subject having cystic fibrosis, the method comprising:
administering to the subject by inhalation a therapeutically effective amount of a composition comprising a derivatized chitosan, wherein the derivatized chitosan comprises a chitosan of the following formula (I):
wherein:
n is an integer between 20 and 6000; and
each R 1 is independently selected for each occurrence from hydrogen, acetyl, and a group of formula (II): wherein, formula (II) is selected from
wherein at least 25% of R 1 substituents are H, at least 1% of R 1 substituents are acetyl, and at least 4-30% of R 1 substituents are a group of formula (II), the molecular weight of the derivatized chitosan is between 10,000 and 150,000 Da, and the polydispersity index (PDI) of the derivatized chitosan is between 1.5 and 2.5, wherein, upon administration, the composition disrupts a preformed biofilm in the respiratory system of the subject and reduces the viscosity of viscous sputum in the subject relative to sputum that has not been contacted with the composition.
2. The method of claim 1 , wherein the method comprises increasing the pourability of sputum compared to the sputum that has not been contacted with the composition.
3. The method of claim 1 , wherein the method comprises reducing the viscosity of the sputum by at least 50% compared to the sputum that has not been contacted with the composition.
4. The method of claim 1 , further comprising administering an antibiotic, anti-inflammatory, or mucolytic compound to the subject in conjunction with, prior to, or subsequent to the administration of the composition.
5. The method of claim 1 , wherein the derivatized chitosan is present in the composition at a concentration of about 10 to 250 μg/mL.
6. The method of claim 1 , wherein the molecular weight of the derivatized chitosan is between 15,000 and 100,000 Da.
7. The method of claim 1 , wherein the chitosan is functionalized at between 20% and 30%.
8. The method of claim 1 , wherein the degree of deacetylation (% DDA) of the derivatized chitosan is between 75% and 95%.
9. The method of claim 1 , wherein the polydispersity index (PDI) of the derivatized chitosan is between 1.5 and 2.3.
10. The method of claim 1 , wherein the polydispersity index (PDI) of the derivatized chitosan is between 1.5 and 2.0.
11. The method of claim 1 , wherein the therapeutically effective amount is from about 5 to 500 μg/mL.
12. The method of claim 1 , wherein the method comprises reducing the viscosity of the sputum by at least 80% compared to the sputum that has not been contacted with the composition.
13. A method of reducing the viscosity of viscous sputum in the respiratory system of a human subject having cystic fibrosis, the method comprising:
administering to the subject by inhalation a therapeutically effective amount of a composition comprising a derivatized chitosan, wherein the derivatized chitosan comprises a chitosan of the following formula (I):
wherein:
n is an integer between 20 and 6000; and
each R 1 is independently selected for each occurrence from hydrogen, acetyl, and a group of formula (II): wherein, formula (II) is selected from
wherein at least 25% of R 1 substituents are H, at least 1% of R 1 substituents are acetyl, and at least 4-30% of R 1 substituents are a group of formula (II), the molecular weight of the derivatized chitosan is between 10,000 and 150,000 Da, wherein, upon administration, the composition disrupts a preformed biofilm in the respiratory system of the subject and reduces the viscosity of viscous sputum in the subject by at least 50% relative to the sputum that has not been contacted with the composition.
14. The method of claim 13 , wherein the method comprises reducing the viscosity of the sputum by at least 80% compared to the sputum that has not been contacted with the composition.
15. The method of claim 13 , wherein the molecular weight of the derivatized chitosan is between 15,000 and 100,000 Da.
16. The method of claim 13 , wherein the chitosan is functionalized at between 20% and 30%.
17. The method of claim 13 , wherein the degree of deacetylation (% DDA) of the derivatized chitosan is between 75% and 95%.
18. The method of claim 13 , wherein the therapeutically effective amount is from about 5 to 500 μg/mL.